German Observational Multicenter Study of Patients With Fabry Disease Under Chaperone Therapy With Migalastat-HCl
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Migalastat (Primary)
- Indications Fabry's disease
- Focus Therapeutic Use
- Acronyms FAMOUS
- 04 Jan 2021 Status changed from active, no longer recruiting to completed.
- 12 Mar 2020 Results (N=59), focusing on safety, cardiac, renal and biochemical outcome in males and females with amenable mutations after 12 months of treatement, published in the Clinical Pharmacology and Therapeutics
- 04 Oct 2019 Planned End Date changed from 1 Sep 2019 to 1 Jul 2020.